Mass Screening and Treatment for Reduction of Falciparum Malaria

"Investigation will consist in 1 URDT.~For P. falciparum URDT positive:~* collection of 3x1cm dried blood spots on filter paper~* administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT.~Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo:~* collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention.~* 1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12."

"A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~* The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~* Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~* Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~* Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~* Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary."